Compound 48/80, a Mast Cell Degranulator, Causes Oxidative Damage by Enhancing Vitamin C Synthesis Via Reduced Glutathione Depletion and Lipid Peroxidation Through Neutrophil Infiltration in Rat Livers
Overview
Affiliations
In this study, we examined whether compound 48/80 (C48/80), a mast cell degranulator, causes hepatic oxidative damage in rats. Serum and liver biochemical parameters were determined 0.5, 3 or 6 h after a single treatment with C48/80 (0.75 mg/kg). Serum histamine and serotonin levels increased 0.5 h after C48/80 treatment but diminished thereafter. Increases in serum vitamin C (VC) and transaminases and hepatic hydrogen peroxide, lipid peroxide, and myeloperoxidase levels and a decrease in hepatic reduced glutathione level occurred 0.5 h after C48/80 treatment and further proceeded at 3 h, but these changes diminished at 6 h. Serum lipid peroxide and hepatic VC levels increased 3 h after C48/80 treatment. Hepatic glycogen level decreased 0.5 h after C48/80 treatment and further decreased at 3 h. Pre-administered ketotifen diminished all these changes found at 3 h after treatment, while pre-administered NPC 14686 diminished these changes except changes in serum histamine and serotonin levels. Hepatocellular apoptosis observed at 3 h after C48/80 treatment was attenuated by pre-administered ketotifen and NPC 14686. These results indicate that C48/80 causes oxidative damage by enhancing VC synthesis via reduced glutathione depletion-dependent glycogenolysis and lipid peroxidation through neutrophil infiltration following mast cell degranulation in rat livers.
Current utilization trend of immortalized mast cell lines in allergy research: a systematic review.
Yip A, Lee Y, Kow A, Wong C, Lee M, Tham C Immunol Res. 2025; 73(1):41.
PMID: 39838115 PMC: 11750950. DOI: 10.1007/s12026-024-09562-w.
Meng S, Sun X, Juan Z, Wang M, Wang R, Sun L Front Pharmacol. 2021; 12:704852.
PMID: 34512339 PMC: 8430029. DOI: 10.3389/fphar.2021.704852.
Effects of NO/cGMP inhibitors in a rat model of anaphylactoid shock.
Albuquerque A, Ferreira L, Carvalho M, Capellini V, Evora P, Celotto A Braz J Med Biol Res. 2020; 53(3):e8853.
PMID: 32130289 PMC: 7057939. DOI: 10.1590/1414-431X20198853.
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?.
Pinke K, Zorzella-Pezavento S, de Campos Fraga-Silva T, Mimura L, de Oliveira L, Watanabe Ishikawa L Neurotherapeutics. 2019; 17(1):218-234.
PMID: 31463682 PMC: 7007452. DOI: 10.1007/s13311-019-00775-8.